Description
Terlipressin is a synthetic peptide agonist at vasopressin 1 receptors (AVPR1) and is clinically used to treat portal hypertension by decreasing portal pressure; it is an analog of vasopressin. Terlipressin is a vasopressin analog that exhibits both vasoconstrictive and antihypertensive activities in various models. Terlipressin induces gastroparesis in vivo, increasing slow wave frequency in stomach and intestines. Terlipressin may also improve renal function in subjects with hepatorenal syndrome.
References
Lange M, Van Aken H, Westphal M, et al. Role of vasopressinergic V1 receptor agonists in the treatment of perioperative catecholamine-refractory arterial hypotension. Best Pract Res Clin Anaesthesiol. 2008 Jun;22(2):369-81. PMID: 18683482.
Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol. 2007 Nov 14;13(42):5552-9. PMID: 17948928.
Nowak L, Królczyk G, Sobocki J, et al. Gastric stimulation is effective in reversing vasopressin induced gastroparesis. Folia Med Cracov. 2004;45(1-2):71-9. PMID: 16276827.
Heinemann A, Stauber RE. Effect of terlipressin on in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol. 1996 Jun;24(6):739-46. PMID: 8835750.
